REYKJAVIK, ICELAND and ISAFJORDUR, ICELAND--(Marketwire - June 20, 2011) -
Kerecis Limited, the emerging tissue-regeneration company, today announced that its Chairman G. Fertram Sigurjonsson will make a presentation at Elsevier's IN3 East Investor Conference in Boston (Wednesday, June 22, 8:35 a.m., Hyatt Regency Boston).
Kerecis, which recently raised $1 million in interim financing, is looking to close up to USD $4.3 million by the last quarter of 2011. The money would be used to complete clinical trials of its patent-pending, marine-derived, tissue-regeneration product, which has applications across multiple medical-device sectors including wound care and abdominal wall reconstruction.
Statistics show a large need for wound care. Each year about 6 million Americans suffer from problem wounds caused by diabetes, circulatory problems and other conditions, with 1.1 to 1.8 million new cases added each year.
More than 20 million Americans have diabetes, almost 20 percent of whom are over the age of 60. Fifteen percent of all diabetics will develop problem wounds, and about 82,000 diabetics undergo amputation each year because of such wounds.
G. Fertram Sigurjonsson, Kerecis Co-Founder and Chairman of the Board:
"At the In3East conference we will be updating the investor community about the progress of our business plan to encourage additional investor and potential partner interest in our programs. The clinical development program for our first applications in the chronic wound area continues with great success, and we are about to embark on new multi-center trials in the U.S., which will greatly improve the level of clinical data for our technology."
Kerecis (http://www.kerecis.com) is a development and manufacturing business producing a novel, patent-pending, tissue-regeneration material derived from fish skin to accelerate the healing of wounds and tissue reconstruction. Kerecis' material addresses the large unmet need of the double-digit growth biologics segment of the chronic-wounds and hernia-repair markets. The material offers advantages over existing human- and porcine-derived products, including improved manufacturing economics and lower risk of disease transfer. Since it is derived from fish, the material is both kosher and halal compatible, eliminating cultural and religious constraints on usage, with equivalent or better clinical performance. For more information, e-mail email@example.com or call 703-879-6535 (U.S.) or 354-8494960 (Iceland).
About In3 East
Elsevier's In3 East is the largest annual strategic partnership and investment meeting for senior-level medical technology executives. Several hundred venture capital firms and medical technology companies are expected to be represented at IN3 East to hear the latest updates from senior management teams of emerging medical technology companies seeking funding and/or strategic partnerships.